DSIP: The Sleep Peptide Science Still Can’t Explain

DSIP has one of the strangest records in neuroscience. Swiss researchers isolated it in 1977 from the blood of rabbits in an induced sleep and named it for the slow delta waves it produced. Nearly fifty years later, nobody has found the gene that makes it or the receptor it acts on.

This guide covers what DSIP is, what the original experiments showed, why later results conflict, and what to check before ordering research-grade DSIP in Canada.

How DSIP was found

The Basel team’s idea was that sleep might be partly controlled by substances in the blood. They electrically stimulated a region of the thalamus to induce sleep in rabbits, collected blood draining from the brain, dialysed it, and tested the fractions in other animals.

1. 1960s–1970sMonnier’s group in Basel studies “humoral transmission of sleep” using dialysed blood from sleeping rabbits.
2. 1977The active factor is characterized as a nonapeptide and synthesized. In a double-blind study of 58 rabbits, only synthetic DSIP, not its fragments or scrambled analogues, specifically enhanced delta and spindle EEG patterns.
3. 1978A follow-up reports a mean 35% rise in delta activity versus controls, and finds that only the normal α-aspartyl form is active.
4. 1980sReviews by Graf and Kastin describe effects beyond sleep, including on LH, cortisol, growth hormone and ACTH.
5. 2006A review titled “DSIP: a still unresolved riddle” calls the evidence for DSIP as a natural sleep factor weak.

What “delta” means

EEG recordings track the brain’s electrical rhythms. Awake brains produce fast, low-amplitude waves; deep, slow-wave sleep produces slow, high-amplitude delta waves. DSIP got its name because infusing it increased that delta pattern in rabbits.

Why DSIP is still a riddle

Most neuropeptides are understood from the gene up: researchers find the gene, the precursor protein it encodes, the enzymes that cut the active peptide out, and the receptor it binds. DSIP never followed that path. Its gene and precursor have not been identified, and no specific receptor has been confirmed. Some researchers have suggested that the immunoreactivity and activity attributed to DSIP may partly come from a related, still unidentified peptide.

The biological picture is inconsistent too. Sleep effects varied between species, methods and laboratories, some synthetic analogues reportedly acted more strongly than DSIP itself, and studies through the 1980s described effects on stress and reproductive hormones that do not fit a simple sleep-factor story. That uncertainty is why DSIP remains a research compound rather than an established hormone.

What is established and what is open

Related neuro research peptides

DSIP sits in the cognitive and neuro category alongside very different molecules. Semax and Selank are Russian-developed heptapeptides, Epitalon comes from pineal gland research, and our nootropic peptides guide compares the whole group.

DSIPDelta sleep-inducing peptideView product and COA SelankTuftsin-derived heptapeptideView product and COA EpitalonPineal-derived tetrapeptideView product and COA

Sourcing DSIP in Canada

DSIP is short, but one of its quality questions is subtle. Before ordering, check that:

• The mass matches, at about 849 g/mol. See HPLC vs mass spectrometry.
• HPLC purity is reported. The inactive β-aspartyl isomer has exactly the same mass as DSIP, so mass spectrometry alone cannot rule it out. Chromatography is what separates the two.
• The COA matches your lot. How to read a certificate of analysis walks through it.
• Storage is cold, dry and dark. See our peptide storage guide.

Regulatory status in 2026

DSIP had an eventful 2026 for a peptide with no known receptor. In April, Health Canada’s advisory on unauthorized injectable peptides listed DSIP among products it had seized and stated that “For Research Use Only” labelling does not make such products legal or exempt from regulatory requirements.

In the United States, the FDA removed DSIP, under its nonproprietary name emideltide, from Category 2 of its compounding list, the group of substances that raise significant safety risks, and referred it to its Pharmacy Compounding Advisory Committee. At its July 23–24, 2026 meeting, the committee voted against adding emideltide to the list of substances pharmacies may compound. It was the only one of the seven peptides reviewed that the committee rejected, and FDA staff had recommended against all seven. That outcome fits the science above: a peptide whose origin, receptor and natural role remain unresolved.

Frequently asked questions